Recursion is "maintaining our guidance of over $100 million in partnership inflows by year-end 2026 that we laid out in May of this year." The cash position is projected to provide "runway through the ...
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback